HYDERABAD, India, May 24, 2018 /PRNewswire/ --
Granules India Ltd., a growing pharmaceutical manufacturing company,announced today financial results for its fourth quarter and financial year ended 31st March, 2018.
(in INR Crs.)
Consolidated Financials FY 2017-18 Q4 - FY'18 TOTAL INCOME 1,703513 EBITDA 289 53 PAT 133 20
The Company's standalone Total Income during the year was INR 1,678 Cr. In this year the Company recorded EBITDA and PAT of INR 317 Cr. and INR 139 Cr. respectively.
The Company's Board of Directors has proposed a final dividend of 25 paise /share of face value of Rs. 1 each.
"I am happy to share that our full-year revenues have shown a steady growth in the currently challenging scenario faced by the sector as a whole. During the year, there were certain macro and industry developments which did not allow our growth in revenue to reflect in profitability, which is attributable to increased cost of materials. Even as there is uncertainty on when these pressures will abate, we are working towards enhancing and strengthening our infrastructure and product portfolio. We continue to improve our regulatory compliance framework and completion of US FDA audits at four of our sites in the last financial year validates our position. We have built capacity and infrastructure to support our business expansion plans and look forward to consolidating our key investments going forward and focus on execution of our strategies." said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited.
About Granules India Ltd. (BSE: 532482) (NSE: GRANULES)
Granules India is a growing pharmaceutical manufacturing company with best-in-class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K.
Media Contact: Hari Prasad firstname.lastname@example.org +91-9618883774 Concept Public Relations India Limited
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All